Additive and synergistic antitumor effects with toremifene and interferons

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Breast cancer treatment often involves hormone therapy and immunotherapy.
• Understanding drug interactions is crucial for optimizing treatment efficacy.

Purpose of the Study:

• To investigate the in vitro and in vivo effects of toremifene and interferons (alpha and gamma) on cancer growth.
• To evaluate the combined efficacy and potential synergy of toremifene and interferons in cancer treatment.

Main Methods:

• In vitro studies using MCF-7 cells treated with toremifene and interferons, with growth assessed by ATP bioluminescence.
• In vivo studies using rats with DMBA-induced tumors treated with toremifene and rat gamma interferon, with tumor growth monitored by palpation.

Main Results:

• Both toremifene and interferons inhibited MCF-7 cell growth in vitro.
• In vitro, interferons showed additive effects, while toremifene and interferons were additive or synergistic.
• Toremifene inhibited tumor growth in vivo; rat gamma interferon alone had minimal effect.
• The combination of toremifene and gamma interferon was the most effective treatment for DMBA-induced tumors and exhibited no detectable toxicity.

Conclusions:

• Toremifene and interferons demonstrate significant anti-cancer activity both individually and in combination.
• The combination therapy, particularly toremifene with gamma interferon, shows promising efficacy and safety.
• Further clinical studies are warranted to explore the therapeutic potential of combining toremifene and interferons in cancer patients.